CINNAGEN

🇮🇷Iran
Ownership
-
Established
1994-01-01
Employees
-
Market Cap
-
Website

Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients

First Posted Date
2024-05-09
Last Posted Date
2024-08-06
Lead Sponsor
Cinnagen
Target Recruit Count
12
Registration Number
NCT06406153
Locations
🇮🇷

Loghman Hospital, Tehran, Iran, Islamic Republic of

🇮🇷

Clinical Research Development Unit of Akbar Hospital, Faculty of Medicine, Mashhad, Iran, Islamic Republic of

🇮🇷

Growth and Development Research Center, Childrens Medical Center, Tehran, Iran, Islamic Republic of

and more 1 locations

Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma

First Posted Date
2023-04-14
Last Posted Date
2023-04-14
Lead Sponsor
Cinnagen
Target Recruit Count
256
Registration Number
NCT05813470
Locations
🇮🇷

Golestan Hospital, Ahvaz, Iran, Islamic Republic of

🇮🇷

Imam Khomeini, Ahvaz, Iran, Islamic Republic of

🇮🇷

Dr.Tavakoul Office, Karaj, Iran, Islamic Republic of

and more 17 locations

Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration

First Posted Date
2022-10-19
Last Posted Date
2023-02-14
Lead Sponsor
Cinnagen
Target Recruit Count
168
Registration Number
NCT05587062
Locations
🇮🇷

Farabi Hospital, Tehran, Iran, Islamic Republic of

Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine

First Posted Date
2022-03-17
Last Posted Date
2023-08-31
Lead Sponsor
Cinnagen
Target Recruit Count
43
Registration Number
NCT05285384
Locations
🇮🇷

Shaheed Labbafinezhad Hospital, Tehran, Iran, Islamic Republic of

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

First Posted Date
2022-02-16
Last Posted Date
2022-10-18
Lead Sponsor
Cinnagen
Target Recruit Count
168
Registration Number
NCT05242133
Locations
🇮🇷

Sina Hospital, Tehran, Iran, Islamic Republic of

Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years

First Posted Date
2022-02-09
Last Posted Date
2022-10-17
Lead Sponsor
Cinnagen
Target Recruit Count
581
Registration Number
NCT05231590
Locations
🇮🇷

Orchid Life Department, Orchid Pharmed Company, Tehran, Iran, Islamic Republic of

Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine

First Posted Date
2022-01-04
Last Posted Date
2022-10-14
Lead Sponsor
Cinnagen
Target Recruit Count
300
Registration Number
NCT05175625
Locations
🇮🇷

Orchid Life Department, Orchid Pharmed Company, Tehran, Iran, Islamic Republic of

Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

First Posted Date
2021-08-13
Last Posted Date
2022-10-13
Lead Sponsor
Cinnagen
Target Recruit Count
16876
Registration Number
NCT05005559
Locations
🇮🇷

Espinas Palace Hotel, Tehran, Iran, Islamic Republic of

Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis

First Posted Date
2021-07-19
Last Posted Date
2022-10-18
Lead Sponsor
Cinnagen
Target Recruit Count
170
Registration Number
NCT04966338
Locations
🇮🇷

Qaem International Hospital, Rasht, Guilan, Iran, Islamic Republic of

🇮🇷

Qaem Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of

🇮🇷

Sina Hospital, Hamadān, Iran, Islamic Republic of

and more 12 locations

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

First Posted Date
2021-07-12
Last Posted Date
2024-07-26
Lead Sponsor
Cinnagen
Target Recruit Count
214
Registration Number
NCT04957212
Locations
🇮🇷

Qaem Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of

🇮🇷

Amir Hospital, Shiraz, Iran, Islamic Republic of

🇮🇷

Shahid Faghihi Hospital, Shiraz, Iran, Islamic Republic of

and more 41 locations
© Copyright 2024. All Rights Reserved by MedPath